Key Details
Price
$20.79Annual EPS
-$0.36Annual ROE
34.94%Beta
0.05Events Calendar
Next earnings date:
Feb 28, 2025Recent quarterly earnings:
Nov 12, 2024Recent annual earnings:
N/ANext ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Screeners with BCAX included
Market Data
Dividend
Profitability
Efficiency
Valuation
Liquidity
Cash Flow
Institutional Ownership
On track to initiate FORTIFI-HN01, a pivotal Phase 2/3 trial of ficerafusp alfa in 1L R/M HNSCC Completed upsized initial public offering, raising approximately $362 million in gross proceeds, with full exercise of the underwriters' option to purchase additional shares Strong financial position with approximately $521 million in cash and cash equivalents expected to fund operations into the first half of 2029 BOSTON, Nov. 12, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced financial results for the third quarter ended September 30, 2024 and provided a business update. “The third quarter of 2024 was momentous for Bicara, highlighted by the successful completion of our upsized initial public offering, providing us with a robust balance sheet to continue to advance the development of ficerafusp alfa, our bifunctional EGFR/TGF-β inhibitor designed to exert potent anti-tumor activity directly within the tumor microenvironment,” said Claire Mazumdar, PhD, MBA, Chief Executive Officer of Bicara Therapeutics.
24/7 Wall St. Insights Initial public offerings at three biotechs last week tempted insiders to make huge purchases of shares.
BOSTON, Sept. 16, 2024 (GLOBE NEWSWIRE) -- Bicara Therapeutics Inc. (Nasdaq: BCAX), a clinical-stage biopharmaceutical company committed to bringing transformative bifunctional therapies for patients with solid tumors, today announced the closing of its initial public offering of 20,125,000 shares of its common stock at a public offering price of $18.00 per share, which includes 2,625,000 shares issued upon the exercise in full by the underwriters of their option to purchase additional shares of common stock in the offering. Bicara Therapeutics' shares began trading on the Nasdaq Global Market on September 13, 2024 under the ticker symbol “BCAX.” All of the shares of common stock were sold by Bicara Therapeutics.
Six IPOs debuted this past week, including three deals of more than $100 million. Seven IPOs submitted initial filings. Outparcel REIT FrontView REIT filed to raise $100 million, and Chinese on-demand courier service provider BingEx also filed to raise $100 million. No IPOs are currently scheduled to list in the week ahead, as activity remains somewhat muted in the run-up to the 2024 presidential election.
FAQ
- What is the primary business of Bicara Therapeutics Common Stock?
- What is the ticker symbol for Bicara Therapeutics Common Stock?
- Does Bicara Therapeutics Common Stock pay dividends?
- What sector is Bicara Therapeutics Common Stock in?
- What industry is Bicara Therapeutics Common Stock in?
- What country is Bicara Therapeutics Common Stock based in?
- Is Bicara Therapeutics Common Stock in the S&P 500?
- Is Bicara Therapeutics Common Stock in the NASDAQ 100?
- Is Bicara Therapeutics Common Stock in the Dow Jones?
- When was Bicara Therapeutics Common Stock's last earnings report?
- When does Bicara Therapeutics Common Stock report earnings?
- Should I buy Bicara Therapeutics Common Stock stock now?